Research Alliance Corp. II (RACB) plans to redeem all outstanding Class A common stock shares effective December 2, 2022, pending stockholder approval. If approved during the special meeting, operations will cease, and the company will redeem shares at approximately $10.07 each, based on a trust account balance of about $150.7 million. After redemption, RACB intends to liquidate and dissolve, adhering to Delaware law. The company's sponsor has waived redemption rights for certain stocks, while a delisting process from NASDAQ will commence following the actions taken during the special meeting.
POINT Biopharma announced that the U.S. Nuclear Regulatory Commission has issued a Materials License for its new Indianapolis facility, allowing for the handling of nuclear materials. The 80,000-square-foot manufacturing center aims to be a leading radiopharmaceutical production site. This facility will support the Phase 3 clinical trial for metastatic castration resistant prostate cancer later this year. Additionally, POINT has a merger agreement with Research Alliance Corp. I, with plans to trade under the ticker symbol 'PNT' upon completion.
Research Alliance Corp. II (Nasdaq:RACB) has successfully completed its initial public offering, closing on March 22, 2021. The offering consisted of 14,950,000 shares of Class A common stock, including an over-allotment of 1,950,000 shares, priced at $10.00 per share. This resulted in gross proceeds of $149,500,000. Sponsored by RA Capital Management, the company aims to utilize these proceeds for business combinations within the healthcare sector. RACB shares began trading on Nasdaq on March 18, 2021.